Abstract-This study assesses the receptor subtype (AT 1 and AT 2 ) through which angiotensin II (Ang II) mediates contraction in small arteries of young and adult spontaneously hypertensive rats (SHR). Segments of third-order mesenteric arteries (Ϸ200 m in lumen diameter) were mounted in a pressurized system. Systolic blood pressure and media:lumen ratio of small arteries were significantly greater (PϽ0.001) in young SHR and adult SHR than in age-matched Wistar-Kyoto rats (WKY). Ang II-induced contractile effects were significantly increased (PϽ0.05) in young SHR compared with age-matched WKY. AT 1 blockade with losartan, and combined AT 1 and AT 2 blockade with losartan and PD123319, abolished Ang II-stimulated contraction in young and adult rats. AT 2 blockade (PD123319) significantly reduced (PϽ0.01) Ang II-elicited contraction in young SHR but had no effect in WKY or adult SHR, indicating that AT 2 receptors may contribute to Ang II-induced contraction in young SHR. To determine the Ang receptor status in rat mesenteric vessels, AT 1 and AT 2 receptor mRNA expression was determined by reverse transcription-polymerase chain reaction. AT 1 and AT 2 receptor protein expression were detected by Western blot analysis. AT 1 receptor mRNA was equally expressed in age-matched rats, but expression was significantly lower in young rats compared with adult rats. AT 2 receptor mRNA was weakly expressed in WKY and adult SHR. In vessels from young SHR, AT 2 receptor mRNA expression was significantly increased compared with the other groups. AT 1 receptor protein was equally expressed in adult rats of both strains but was undetectable in young rats. AT 2 receptor protein was only detectable in young rats, with the magnitude of expression greater in SHR than WKY. Key Words: resistance Ⅲ arteries Ⅲ hypertension Ⅲ receptors, angiotensin Ⅲ vasoconstriction Ⅲ PD123319 Ⅲ losartan A ngiotensin II (Ang II), the final mediator of the reninangiotensin system, plays a pivotal physiological role in cardiovascular homeostasis. It is a potent vasoconstrictor of the peripheral vasculature and induces hypertrophy, hyperplasia, or both in small resistance arteries, in vascular smooth muscle cells, in endothelial cells, and in cardiomyocytes. [1] [2] [3] [4] Because of these actions, Ang II may play an important pathophysiological role in the development and maintenance of hypertension.
A ngiotensin II (Ang II), the final mediator of the reninangiotensin system, plays a pivotal physiological role in cardiovascular homeostasis. It is a potent vasoconstrictor of the peripheral vasculature and induces hypertrophy, hyperplasia, or both in small resistance arteries, in vascular smooth muscle cells, in endothelial cells, and in cardiomyocytes. [1] [2] [3] [4] Because of these actions, Ang II may play an important pathophysiological role in the development and maintenance of hypertension.
Cellular responses to Ang II are mediated by specific cell membrane receptors. Two main subtypes of Ang receptors have been pharmacologically defined: AT 1 and AT 2 , which are blocked specifically by losartan and PD123319, respectively. [5] [6] [7] AT 1 has 2 subtypes in rodents, AT 1A and AT 1B , with greater than 95% amino acid sequence homology. 6 Most of the known physiological effects of Ang II are mediated by AT 1 receptors and, until recently, it was believed that vascular Ang II receptors were exclusively of the AT 1 subtype. However, it has recently been demonstrated that the adult rat aorta expresses a small but significant amount of AT 2 receptors as well. 8 In the aortas of fetal and young rats, the proportion of AT 2 receptors is higher, and this predominance of AT 2 receptors is reversed during development. 8, 9 In 2-week-old Sprague-Dawley rats, 81% of Ang receptors in the aorta are of the AT 2 subtype, and in 8-week-old rats, this is reduced to 28%, with a predominance of AT 1 (71%). 8 In 6-to 8-week-old spontaneously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY), renal resistance vessels display 20% of Ang II binding sites with affinity for PD123319. 10 AT 2 receptors may be important in tissue growth and development. Growth-promoting effects of Ang II appear to be mediated primarily via AT 1 receptors, 6, 9, 11 and antiproliferative effects have been linked to AT 2 receptors. 6 A study by Stoll et al 12 demonstrated an antiproliferative effect of Ang II on coronary endothelial cells, which could be blocked by PD123177 (an AT 2 antagonist). Saward and Zahradka 13 reported that PD123319, but not losartan, could block Ang II-induced RNA synthesis in A10 vascular smooth muscle cells. Levy et al 14 recently reported that blood pressure remained high in Wistar rats treated for 3 weeks with Ang II and PD123319 but that fibrosis and vascular hypertrophy were reduced by PD123319 compared with Ang II infusion alone.
AT 2 receptors have also been implicated in pathological conditions associated with cardiovascular remodeling. In neointimal formation after vascular injury, AT 1 receptor expression is changed to that of the AT 2 subtype 15 ; in diabetes, 16 postmyocardial infarction, 17 ischemia, 18 and hypertension, 19 AT 2 receptor expression may be enhanced. Also, vascular responsiveness to Ang II is altered in hypertension. In SHR with established hypertension, vascular reactivity to Ang II is increased or unchanged, 20, 21 and in portal hypertension, mesenteric artery responses to Ang II are reduced. 22 We and others have shown that Ang II-stimulated [Ca 2ϩ ] i and vascular responses are exaggerated in smooth muscle cells from mesenteric arteries of SHR. 23, 24 In young SHR and stroke-prone SHR, renal vascular responses to Ang II are augmented. 25, 26 Underlying mechanisms for altered Ang II-elicited vascular responses in hypertension are unclear, but changes in receptor status may play a role.
The aims of the present study were (1) to determine the receptor subtype through which Ang II mediates contraction in young and adult SHR, (2) to evaluate the vascular AT 1 and AT 2 receptor status by determining mRNA expression of the 2 receptor subtypes in rat small mesenteric arteries, and (3) to assess whether AT 1 and AT 2 receptor mRNA and protein expression is altered in SHR. Contractile effects of Ang II were assessed in mesenteric resistance vessels from 6-weekold SHR in the phase of developing high blood pressure, and in 21-week-old SHR in the phase of established hypertension. Age-matched normotensive WKY were also studied. Arteries were mounted as pressurized preparations, which facilitates assessment of vessels in conditions that resemble those in vivo. 27 
Methods

Materials
Ang II was obtained from Peninsula Laboratories Inc. PD123319 was from Research Biochemicals International. AT 1 (N-10) rabbit polyclonal antibody and AT 2 (C-18) goat polyclonal antibody were bought from Santa Cruz Biotechnology Inc. All other chemicals were obtained from Sigma Chemical, Fischer Scientific, and BDH Inc.
Rats
Animal experiments were performed according to the recommendations of the Canadian Council for Animal Care and were approved by the Animal Care Committee of the Clinical Research Institute of Montreal. Male SHR and WKY 5 and 20 weeks of age were acquired from Taconic Farms Inc. (Germantown, NY). They were housed under standardized conditions with controlled temperature (22°C) and humidity (60%) and exposed to a 12-hour ligh/dark cycle. They were fed regular pelleted rat chow and given tap water ad libitum. Indirect systolic blood pressure was measured by the tail-cuff method in conscious prewarmed slightly restrained animals 3 to 4 days before experimentation. Blood pressure was recorded with a model PCPB photoelectric pulse sensor on a Grass model 7 polygraph fitted with a 7P8 preamplifier (Grass Medical Instruments). The average of 3 pressure readings was recorded.
Preparation and Mounting of Small Arteries
Rats were euthanized by decapitation. Superior mesenteric arteries were taken from the part of mesenteric bed that feeds the jejunum 8 to 10 cm distal to the pylorus, were dissected out, and were immediately placed in cold physiological salt solution (PSS) of the following composition (mmol/L): NaCl 120, NaHCO 3 The arterial segments were mounted as pressurized preparations as previously described. 27, 28 Arteries (Ͻ280 m diameter and 2 to 3 mm in length) were mounted onto 2 glass microcannulae. One cannula was fixed, whereas the other was adjustable and could be positioned as appropriate. Both ends of arterial segments were secured to the cannula with nylon suture. The axial length of the arterial segments was adjusted by carefully moving the cannula until the vascular walls were parallel without any buckling or stretching. The vessels were pressurized to 45 mm Hg, considered the optimum pressure, because contractile responses reach a maximum at this intraluminal pressure as shown in preliminary studies. After applying intraluminal pressure, the arteries were checked for leaks, which were identified by a reduction in the preset intraluminal pressure. The arterial segments were then allowed to equilibrate for 45 to 60 minutes. A viability test was performed in all arteries, and only those segments in which an extraluminal application of KSS (ie, PSS that contained 125 mmol/L KCl) containing 10 mol/L norepinephrine, induced vasoconstriction toϾ50% of their resting lumen diameter were considered viable. The integrity of vascular endothelium was confirmed if arterial segments dilated in response to an extraluminal application of 10 mol/L acetylcholine in PSS containing 10 mol/L norepinephrine.
Experimental Protocol
After each activation, the arterial segments were perfused with PSS and allowed to regain their resting diameter. Media thickness and lumen diameter were then measured. Measurements were made from the transillumination image with a microcomputer-based videoimaging system at 3 points along a portion of each vessel, and the mean value was calculated. The arteries were perfused extraluminally at a rate of 2 mL/min with PSS containing Ang II (10 -11 to 10 -6 mol/L) to obtain cumulative concentration-response curves. In the case of antagonists, the arteries were preincubated with drugs 15 minutes prior to starting the experiments. The arteries were stimulated at each concentration until the maximal decrease in lumen diameter was obtained. Each arterial segment was used for only 1 Ang II concentration-response curve.
Reverse Transcription-Polymerase Chain Reaction Analysis of AT 1 and AT 2 Receptors
AT 1 and AT 2 receptor mRNA expression was measured by reverse transcription-polymerase chain reaction (RT-PCR). Total RNA was extracted from mesenteric arteries using TRIzol (GIBCO Life Technologies). Total RNA samples were treated with RNAse-free DNAse (GIBCO Life Technologies), and contamination of sample RNAs by genomic DNA was excluded by directly subjecting the sample RNAs to PCR amplification without a RT step. Total RNA from adrenal gland was used as a positive control for AT 1 and AT 2 receptors in RT-PCR. Water was used as a negative control.
Reverse transcription was performed in a reaction volume of 30
, and 3 L of dithiothreitol 0.1 mol/L at 37°C for 1 hour. The reaction was inactivated at 95°C for 5 minutes. After first-strand synthesis of RNA, 2 L cDNA was then amplified using specific primers. For amplification of AT 1 receptor cDNA, the sense primer 5Ј GTAGC CAAAG TCACC TGCAT 3Ј (extending from base 568 through base 587) and the antisense primer 3Ј TATCG AATAA AATTG TTAAC GGACT 5Ј (extending from base 1006 through base 1030) were used. For amplification of AT 2 receptor cDNA, the sense primer was 5Ј ACCTG CATGA GTGTT GATAGG 3Ј (extending from base 545 through base 565), and the antisense primer was 3Ј ACTTCA ATATC GTCAGT AACTGGAC 5Ј (extending from base 1010 through base 1033). For glyceraldehyde phosphate dehydrogenase (GAPDH), the sense primer was 5Ј TATGA TGACA TCAAG AAGGTGG 3Ј(extending from base 827 through base 848), and the antisense primer was 3Ј ATGTC GTTGT CCCAC CAC 5Ј (extending from base 1023 through base 1040). The amplification profile involved denaturation at 95°C for 30 seconds, annealing at 57°C for 30 seconds, and extension at 72°C for 30 seconds for 30 cycles. After amplification, PCR products were electrophoresed on a 1.5% agarose gel for 1 hour at 9V/cm gel. Bands corresponding to RT-PCR products were visualized by UV light after agarose gel electrophoresis, and their intensities were measured by densitometry.
Western Blot Analysis of Vascular AT 1 and AT 2 Receptors
Mesenteric arteries, isolated from young and adult WKY and SHR (nϭ3 per group), were homogenized with VARI-MIX III (Caulk Dentsply Co, Toronto, Ontario, Canada). The homogenate was incubated on ice for 30 minutes in PBS containing 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 10 mg/mL phenylmethylsulfonyl fluoride, and 10 U/mL aprotinin, followed by centrifugation at 15 000g for 20 minutes at 4°C. The protein concentration was determined with Micro BCA Protein Assay Kit (Pierce). After denaturation at 100°C for 5 minutes, equal amounts of proteins (20 g) were loaded on a 12% sodium dodecyl sulfatepolyacrylamide gel and transferred to polyvinylidene fluoride membrane for 1 hour at 100 V at 4°C. Membranes were blocked overnight at 4°C in 5% milk washing solution (50 mmol/L Tris-HCl, 200 mmol/L NaCl, 0.1% Tween-20, pH 7.4). Membranes were incubated with rabbit polyclonal antibody against AT 1 receptor (Ϸ50 kDa) or goat polyclonal antibody against AT 2 receptor (Ϸ44 kDa) (Santa Cruz) diluted 1:100 or 1:200, respectively, in washing solution at room temperature for 1 hour. The membranes were then washed, incubated with anti-rabbit or anti-goat horseradish peroxidase-conjugated second antibody 1:5000 (or 1:2000) for 1 hour at room temperature, and washed extensively. Membranes were incubated with Chemiluminescence Blotting Substrate (Boehringer Mannheim), according to the manufacturer's protocol, and exposed to film that was immediately developed. The film was scanned by ScanJet 6100C/T (Hewlett Packard) and saved to a computer. Band intensity was measured by computer analysis, using the Image Quant program (Molecular Dynamics).
Statistical Analysis
Contractile responses to Ang II were calculated by measurement of percentage decrease in resting diameter relative to the response to 10 mol/L norepinephrine. Lumen diameter was significantly smaller (PϽ0.001), and media:lumen ratio and media thickness were significantly greater (PϽ0.001) in SHR than in age-matched WKY (Table  1) . Media cross-sectional area was similar in 6-week-old SHR and WKY, but in 21-week-old rats it was greater in SHR than WKY (PϽ0.05; Table 1 ). Cross-sectional area was significantly greater (PϽ0.001) in adult SHR than in young SHR.
Contractile Effects of Ang II
Application of Ang II reduced lumen diameter in a concentration-dependent manner in vessels from young and adult rats. In young rats, contractile responses induced by Ang II were significantly greater in SHR than in WKY (Table 2, Figure 1 ). Ang II-stimulated contraction in 21-week-old SHR was slightly greater than that in vessels of age-matched WKY,but only reached statistical significance (PϽ0.05) at 10 -9 mol/L Ang II. Sensitivity to Ang II was significantly greater in arteries from adult SHR than in age-matched WKY (Table 2) . Vascular contractile responses in SHR were significantly greater in young prehypertensive rats compared with adult rats ( Table 2) .
Effects of Losartan and PD123319 on Ang II-Stimulated Contraction
To determine the receptor subtype through which Ang II mediates vascular contraction, vessels were preexposed to the selective AT 1 antagonist losartan or the selective AT 2 receptor-blocker PD123319. In young rats, PD123319 had no significant effect on Ang II-induced contraction in WKY but significantly attenuated maximum responses in SHR (PϽ0.05; Figure 1 , Table 2 ). In adult rats, PD123319 had no significant effect on Ang II-elicited maximal contractile responses in SHR or WKY (Figure 2 ). Losartan inhibited Ang II effects but did not completely block contractile responses induced by high Ang II concentrations in SHR arteries (Figures 1 and 2 ). Pretreatment with losartan and PD123319 in combination completely abolished Ang II-stimulated contractions in young and adult WKY and SHR (Figures 1 and 2 ).
Expression of AT 1 and AT 2 Angiotensin Receptors
Figures 3 and 4 are representative examples of the PCR products for young and adult WKY and SHR. The amounts of vascular AT 1 and AT 2 receptor mRNA were measured by scanning and expressed as arbitrary units (Figures 3 and 4) . Figure 5 demonstrates the meanϮSEM for the amounts of vascular AT 1 and AT 2 receptor mRNA, expressed as a ratio to GAPDH mRNA, in the different groups (nϭ3 per group). AT 1 receptor mRNA was equally expressed in age-matched WKY and SHR (Figures 3 and 5) . However, compared with adult rats, AT 1 mRNA expression was significantly less in young rats (Figures 3 and 5) . AT 2 receptor mRNA was weakly expressed in mesenteric arteries from WKY and adult SHR (Figures 4 and 5) . In young SHR, AT 2 receptor mRNA expression was greater compared with age-matched WKY and adult SHR (Figures 4 and 5 ).
Western Blot Analysis of Vascular AT 1 and AT 2 Receptors
Western blot analysis demonstrated that the AT 1 receptor protein was detectable in mesenteric vessels from adult WKY and SHR but not from young rats of either strain ( Figure 6 ). The AT 2 receptor protein was weakly expressed in young rats, with the magnitude of expression being higher in vessels from SHR than in WKY ( Figure 6 ). AT 2 receptor protein was undetectable in vessels from adult rats of either strain ( Figure  6 ). PC12W cells, which express AT 2 receptors exclusively, were used as a positive control for AT 2 receptor protein.
Discussion
Results from the present study demonstrate that in the phase of developing hypertension in SHR Ang II-stimulated contraction is mediated via AT 1 receptors and receptors that are blocked by PD123319, probably AT 2 receptors, whereas in adult SHR with established hypertension Ang II-induced vasoconstriction is mediated exclusively via AT 1 receptors. The pharmacological findings are supported by molecular data, where AT 2 receptor expression was increased only in arteries from young SHR. These novel data in young SHR provide important information regarding the vasoconstrictor effects of Ang II that may be involved in vascular dysfunction associated with the development of spontaneous hypertension.
Ang II dose-dependently contracted small arteries from WKY and SHR. Using a preparation similar to the one described here, Falloon et al also demonstrated a contractile effect of Ang II on small mesenteric arteries from WKY. 29 Responsiveness in vessels from 6-week-old SHR was significantly greater than in WKY and adult SHR. Vascular hyperresponsiveness to Ang II in young SHR and stroke- prone SHR has also been demonstrated in renal vessels. 25, 26 Ang II-elicited vascular hyperresponsiveness in the early phase of blood pressure elevation may represent a critical phase in the development of hypertension in this genetic model of hypertension. In support of this are studies that examined long-term cardiovascular effects after a brief period of angiotensin-converting enzyme inhibitor treatment in young SHR. 19, 30 SHR treated with perindopril from 6 to 10 weeks of age was sufficient to prevent the full expression of genetic hypertension and cardiovascular hypertrophy. 30 Underlying mechanisms for Ang II-related changes in the early phase of blood pressure elevation could be due to alterations in Ang II receptor status. 31 Results from our study demonstrate that the selective AT 2 receptor blocker PD123319 had no effect on Ang II-mediated contraction in vessels of WKY or adult SHR. However, Ang II-stimulated contraction was significantly attenuated in young SHR, suggesting that in the early phase of blood pressure elevation, PD123319-sensitive receptors, which are probably AT 2 receptors, also play a role in Ang II-mediated vasocontraction. Selective blockade of the AT 1 subtype antagonized the constrictor actions of Ang II in all groups. These data indicate that in normotensive rats and in SHR with established hypertension, Ang II-induced vasoconstriction in small mesenteric arteries is mediated exclusively via AT 1 receptors, whereas in young SHR Ang II-stimulated contraction is associated with AT 1 -and PD123319-sensitive receptors, which may be AT 2 receptors. Our findings are in agreement with those of others who recently demonstrated that in young rats, Ang II induces vasoconstriction in renal arteries via AT 1 -and PD123319-sensitive receptors (J.W. Arendshorst, personal communication, 1998). AT 2 receptor-mediated vasoconstriction has been implicated in cerebral arteries 32 and in renal vasoconstriction in hydronephrotic rat kidneys. 33 Other studies have shown that AT 2 receptors mediate 20% of Ang II-induced renal vasoconstriction in SHR during the development of hypertension. 10 Furthermore, AT 2 receptors are reexpressed in various pathological states of the vasculature, including hypertension. 16 -19 The exact mechanism or mechanisms underlying AT 2 -associated vasoconstriction are unclear, but the interplay between AT 1 and AT 2 receptor stimulation in young SHR could be important. Our data demonstrate that Ang II-induced contraction in young SHR is mediated essentially via AT 1 receptors (Ϸ90%), and that AT 2 receptors contribute Ϸ20%. Because the magnitude of the losartan-insensitive contractile component is less than that of the PD123319-sensitive component, it may be plausible that AT 2 -receptor stimulation could modulate AT 1 receptor-mediated vasoconstriction. It is also possible that other Ang II receptor subtypes, which have not yet been characterized, may also be playing a role. Hayashi et al 33 reported that PD123319 in addition to binding to AT 2 receptors also binds to AT 1 , particularly AT 1B receptor subtypes. This is probably not the case in the present study, because PD123319 did not alter contraction in young WKY and adult rats but had an effect only on vessels from young SHR, which have increased AT 2 mRNA and protein levels. Although our data suggest that AT 2 receptors may play a role in vasoconstriction in the development of hypertension, most previous studies, which were conducted mainly in normotensive rats, demonstrated that AT 2 -receptor stimulation mediates signaling pathways associated with vasodilation 34 -36 and inhibition of cell growth. 37, 38 Recent data, however, implicate that vascular remodeling in hypertension is mediated in part via AT 2 receptors. 14, 39, 40 The exact role of the vascular AT 2 receptor subtype in the development of hypertension is unclear and awaits further clarification.
To investigate in greater detail the significance of Ang receptor subtypes in mesenteric arteries from SHR, molecular techniques were used to assess AT 1 and AT 2 receptor mRNA and protein expression. AT 1 receptor mRNA expression was not different between age-matched WKY and SHR but was significantly greater in adult rats than in young rats. Our results are in agreement with other studies that demonstrate that AT 1 receptors are the major receptor subtype in adult tissue. 41, 42 AT 2 receptor mRNA was weakly expressed in vessels from WKY and adult SHR. However, in arteries from young SHR, AT 2 receptor mRNA expression was markedly elevated. These data are supported by results obtained from Western blot analysis, which demonstrate that AT 1 -receptor protein expression is similar between age-matched rats, whereas AT 2 -receptor protein expression is increased in young SHR compared with young WKY. AT 2 -receptor protein was undetectable in arteries from adult rats. Previous studies have reported that AT 2 receptors are reexpressed or upregulated in experimental cardiac hypertrophy, myocardial infarction, and neointimal lesions after vascular injury, [43] [44] [45] [46] but to the best of our knowledge, data from the present study are the first to demonstrate differential AT 2 receptor mRNA and protein expression in mesenteric arteries from SHR in different phases in the development of hypertension.
In conclusion, the present study demonstrates that young SHR have elevated blood pressure, significant vascular hypertrophy, enhanced Ang II-stimulated responsiveness of small mesenteric arteries, increased vascular expression of AT 2 receptor mRNA, and involvement of both AT 1 -and PD123319-sensitive receptors (probably AT 2 ) in Ang IImediated contraction. In adult SHR with established hypertension, Ang II-elicited contraction is mediated exclusively via AT 1 receptors. Thus, augmented Ang II vascular responsiveness in young SHR may be associated with changes in Ang II receptor status, which could contribute to the development of high blood pressure in this model of genetic hypertension.
